Psoriasis Skin and Connective Tissue Diseases Psoriasis
Conditions
Interventions
30 patients will be recruited to the study in two groups of 15. All patients will have psoriasis and have routinely been prescribed narrowband UVB treatment for this. Patients will be recruited direct
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. At least 18 years of age 2. Able to speak English 3. Able to provide written informed consent 4. Have chronic plaque psoriasis 5. Prescribed NbUVB phototherapy 6. Able and willing to attend the phototherapy department regularly
Exclusion criteria
Exclusion criteria: 1. Able to control their psoriasis or already controlled by topical therapy 2. Pregnant 3. Significant sun exposure, sun-bed use or previous NbUVB within the last month or be planning significant sun exposure or sun-bed use in the next month 4. Previously taken, in the last three months any of the following: methotrexate, azathioprine, ciclosporin, biological therapy or systemic steroids for treatment of psoriasis 5. Previously taken, in the last month, any oral photosensitising medications, including: thiazide diuretics, antibiotics such as tetracyclines and quinolones, non-steroidal anti-inflammatory drugs, phenothiazines, retinoids, sulphonylureas, quinine and St John’s Wort 6. Also suffer from diseases where phototherapeutic treatment is contraindicated: xeroderma pigmentosum, lupus erythematosus 7. Work night-shifts 8. Diagnosed circadian rhythm disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of apoptosis in skin biopsies, measured by manual and automated counts of histology slides at 24 hours after irradiation with narrowband UVB light (day 3) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Minimal erythema dose (that is, comparing the skin's sensitivity to UV in the am and pm) measured visually, in line with current clinical practice, with the aid of an erythema meter, at 24 hours after test irradiation (day 2)) 2. Salivary cortisol levels in patients with psoriasis and associated circadian rhythm dysfunction, measured by ELISA at the following timepoints on days 1, 2 and 3: waking, 0900, 1600, before sleep 3. Urinary melatonin levels in patients with psoriasis and associated circadian rhythm dysfunction, measured by ELISA from an early morning urine sample on days 2 and 3 4. Sleep quality measured by Pittsburgh Sleep Quality Index and Morningness-Eveningness Questionnaire at baseline 5. Symptoms of anxiety and depression measured with the Dermatology Life Quality Index, Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 at baseline | — |
Countries
United Kingdom
Outcome results
None listed